Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.1% – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s share price dropped 6.1% on Tuesday. The company traded as low as $33.04 and last traded at $32.9330. Approximately 497,334 shares were traded during trading, a decline of 46% from the average session volume of 920,710 shares. The stock had previously closed at $35.06.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. Citizens Jmp reissued a “market outperform” rating and set a $110.00 price objective on shares of Structure Therapeutics in a report on Wednesday, September 9th. Weiss Ratings downgraded Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Trading Down 6.4%

The company has a 50 day moving average of $46.25 and a 200 day moving average of $46.43. The firm has a market cap of $2.29 billion, a price-to-earnings ratio of -32.83 and a beta of -1.45.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. IFP Advisors Inc acquired a new position in shares of Structure Therapeutics during the second quarter worth $46,000. Squarepoint Ops LLC raised its stake in shares of Structure Therapeutics by 454.5% during the 2nd quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock worth $6,740,000 after purchasing an additional 102,929 shares during the period. Seven Fleet Capital Management LP raised its stake in shares of Structure Therapeutics by 197.8% in the second quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company’s stock valued at $1,442,000 after buying an additional 17,800 shares during the period. Wellington Management Group LLP raised its position in shares of Structure Therapeutics by 1.6% in the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after purchasing an additional 119,146 shares during the period. Finally, Handelsbanken Fonder AB bought a new position in shares of Structure Therapeutics in the second quarter valued at approximately $1,041,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions.

Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes.